Allergic conjunctivitis

The conjunctivitis therapeutics market will register a CAGR of over 8% by 2023

Retrieved on: 
Tuesday, February 12, 2019
Medicine, Immunology, RTT, Health care, Allergology, Conjunctivitis, Measles, Immune system, Allergic conjunctivitis, Allergy

While allergic conjunctivitis is known to be prevalent among people with allergies, infectious conjunctivitis is known to spread at a very fast rate.

Key Points: 
  • While allergic conjunctivitis is known to be prevalent among people with allergies, infectious conjunctivitis is known to spread at a very fast rate.
  • Technavio's analysts have predicted that the conjunctivitis therapeutics market will register a CAGR of over 8% by 2023.
  • One of the major challenges faced by the global conjunctivitis therapeutics market is the patent expiration of various drugs in the market.
  • For the detailed list of factors that will drive and challenge the growth of the conjunctivitis therapeutics market during the 2019-2023, view our report.

Allergic Conjunctivitis - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 31, 2019
Health, Pharmaceutical, Medical specialties, Medicine, Immunology, RTT, Allergic conjunctivitis, Allergology, Conjunctivitis, Drug pipeline, Allergy

The "Allergic Conjunctivitis - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Allergic Conjunctivitis - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Allergic Conjunctivitis - Pipeline Insight, 2019 offers a comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Allergic Conjunctivitis development.
  • The report covers pipeline activity across the complete product development cycle i.e.
  • clinical, pre-clinical and discovery stages for the Allergic Conjunctivitis
    The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
    Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Allergic Conjunctivitis

Global Allergic Conjunctivitis API Manufacturers, Marketed and Phase III Drugs Landscape, 2019-2021: Route of Synthesis, Regulatory Milestones, & Forecasted Sales Estimates

Retrieved on: 
Thursday, January 24, 2019
Medical specialties, Medicine, Immunology, RTT, Allergology, Allergic conjunctivitis, Conjunctivitis, Allergy

The "Allergic Conjunctivitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Allergic Conjunctivitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Allergic Conjunctivitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Allergic Conjunctivitis .
  • Coverage of API manufacturers for Allergic Conjunctivitis marketed products spanning across United States, Europe, China and India.
  • A review of the marketed products for Allergic Conjunctivitis including their description, route of synthesis, regulatory milestones, forecasted sales estimates till 2021 and API manufacturer details.

Global Allergic Conjunctivitis Report 2019 - API Manufacturers, Marketed and Phase III Drugs Landscape - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 24, 2019
Health, Pharmaceutical, Medicine, Immunology, RTT, Health care, Allergology, Allergic conjunctivitis, Conjunctivitis, Allergy

This report provides comprehensive insights about marketed and Phase III products for Allergic Conjunctivitis .

Key Points: 
  • This report provides comprehensive insights about marketed and Phase III products for Allergic Conjunctivitis .
  • The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country.
  • Coverage of API manufacturers for Allergic Conjunctivitis marketed products spanning across United States, Europe, China and India.
  • This report provides a comprehensive understanding of the emerging Phase III therapies for Allergic Conjunctivitis which can turn out to be future prospective competitors for the marketed products.

Juntendo University Research: Omega-3 Fatty Acids Suppress Allergic Conjunctivitis Symptoms

Retrieved on: 
Tuesday, December 4, 2018
Nutrition, Fatty acids, Health, Medicine, Chemistry, Allergology, Omega-3 fatty acid, Lipid, Fat, Allergic conjunctivitis

Now, a team of researchers from Juntendo University led by Takehiko Yokomizo has shown that in mice, a diet rich in omega-3 fatty acids alleviates AC symptoms in the early and late phases of the disease.

Key Points: 
  • Now, a team of researchers from Juntendo University led by Takehiko Yokomizo has shown that in mice, a diet rich in omega-3 fatty acids alleviates AC symptoms in the early and late phases of the disease.
  • In order to gain insights into why omega-3 fatty acids alleviate AC symptoms, Yokomizo and colleagues analyzed which compounds are present in the conjunctiva.
  • The findings of Yokomizo and colleagues suggest that a diet rich in omega-3 fatty acids may alleviate the symptoms of allergic conjunctivitis in humans.
  • Dietary omega-3 fatty acids alter the lipid mediator profile and alleviate allergic conjunctivitis without modulating Th2 immune responses.

Aldeyra Therapeutics Announces Second Quarter 2018 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 9, 2018
Allergic conjunctivitis, Allergology, Health care, Health

LEXINGTON, Mass., Aug. 9, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results for the second quarter ended June 30, 2018 and provided a corporate update.

Key Points: 
  • LEXINGTON, Mass., Aug. 9, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results for the second quarter ended June 30, 2018 and provided a corporate update.
  • Phase 2b Clinical Results in Dry Eye Disease Expected in Late Third Quarter or Early Fourth Quarter 2018.
  • Phase 3 Clinical Results from the ALLEVIATE Trial in Allergic Conjunctivitis Expected in Late 2018 or Early 2019.
  • Additional factors may be described in those sections of Aldeyra's Quarterly Report on Form 10-Q for the quarter endedJune 30, 2018, expected to be filed with theSECin the third quarter of 2018.